Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation

BACKGROUND: Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawerkamp, Heike C., Domdey, Alina, Radau, Lisa, Sewerin, Philipp, Oláh, Péter, Homey, Bernhard, Meller, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138978/
https://www.ncbi.nlm.nih.gov/pubmed/34020693
http://dx.doi.org/10.1186/s13075-021-02509-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138978/
https://www.ncbi.nlm.nih.gov/pubmed/34020693
http://dx.doi.org/10.1186/s13075-021-02509-8

Ejemplares similares